Genitourinary Syndrome of Menopause in Breast Cancer
About this study
This randomized, single-blind clinical trial will compare the effectiveness of multimodal pelvic floor physiotherapy (PPT) and fractional CO2 vaginal laser therapy in reducing genitourinary syndrome of menopause (GSM) symptoms among breast cancer (BC) survivors. GSM, induced by cancer treatments, is common in BC survivors due to hormonal deprivation, and effective non-hormonal treatments are needed. The study will enroll 210 women diagnosed with GSM following BC treatment, who will be randomly assigned to either three sessions of CO2 vaginal laser therapy or eight sessions of multimodal PPT, which includes pelvic floor muscle training, vaginal non-ablative radiofrequency, education, and moisturizers. Primary outcomes will include perineal pain, sexual function, and health-related quality of life (HRQoL), with assessments at baseline, post-intervention, and at 3, 6, and 12 months. The hypothesis is that multimodal PPT will lead to greater improvements in pelvic pain, muscle function, and sexual health, with sustained benefits over time. This trial aims to provide evidence for non-invasive, non-hormonal treatments to manage GSM in BC survivors, filling a significant therapeutic gap.
- Condition
- Genitourinary Syndrome of Menopause (GSM), Breast Cancer Female
- Tested
- Multimodal pelviperineal physioterapy group, Laser CO2 Therapy group
- Sponsor
- University of Alcala
Who can join
- Age
- 38 years and older
- Sex
- Female only
- Healthy volunteers
- Not accepted
Inclusion 5
- Minimum age: 38 years
- Eligible sex: Female
- Study condition: Genitourinary Syndrome of Menopause (GSM), Breast Cancer Female
- Breast cancer survivors diagnosed with GSM as a result of cancer treatment
- Vaginal Health Index (VHI) score of ≤ 15.
Exclusion 3
- History of conservative treatment or surgery for pelvic floor dysfunction or GSM
- Currently undergoing chemotherapy, or have undergone BC surgery but have not received chemotherapy or hormonal treatment.
- Presence of concomitant or systemic diseases that could interfere with the proposed treatments, such as a recurrence of the oncological process, active or recurrent untreated urinary tract infections, hematuria, or cognitive impairments that hinder the participant's ability to comprehend study information, respond to questionnaires, provide informed consent, or fully participate in the study.
Where
1 site, 1 recruiting
Hospital Universitario Ramón y Cajal
Madrid, Spain
Contact
-
María Torres Lacomba, Full Professor
34918854828 maria.torres@uah.es
Potential match only. Final eligibility is determined by the study team.